Intelligence · Clinical Pipeline
ALMIRALL S.P.A Pipeline
All ClinicalTrials.gov programs at ALMIRALL S.P.A — phase, modality, and trial IDs.
- Programs
- 3
Quick answer
ALMIRALL S.P.A has 3 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
-
Ebglyss 250 mg solution for injection in pre-filled syringe, Placebo, Ebglyss 250 mg solution for injection in pre-filled pen
Almirall, S.A.
Atopic Dermatitis
1 trial -
Placebo, Ebglyss 250 mg solution for injection in pre-filled syringe
Almirall, S.A.
Nummular Dermatitis
1 trial -
TIRBANIBULIN, Placebo of the new presentation of 350 mg/sachet drug product (hereafter referred as vehicle) is a smooth, creamy white to off-white ointment free from foreign particles, packed intact and properly sealed containing the same qualitative composition as the active product but without the active substance. The vehicle will be provided in a single-use packets to contain 350 mg of drug product., Klisyri 10 mg/g ointment
Almirall, S.A.
Actinic Keratosis on the Face or Scalp
1 trial
Frequently asked questions
How many pipeline programs does ALMIRALL S.P.A have?
3 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.
Data attribution: Data sources · All pipeline programs